Which has preferable valuation and earnings, PEN or LNTH?

Lantheus has higher revenue and earnings than Penumbra. Lantheus is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Penumbra $1.40B 8.92 $177.69M $4.07 78.10 Lantheus $1.54B 4.24 $233.56M $4.14 24.21

Is PEN or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to Penumbra's net margin of 10.67%. Lantheus' return on equity of 28.10% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Penumbra 10.67% 10.50% 8.17% Lantheus 17.69% 28.10% 14.35%

Does the media refer more to PEN or LNTH?

In the previous week, Lantheus had 1 more articles in the media than Penumbra. MarketBeat recorded 7 mentions for Lantheus and 6 mentions for Penumbra. Penumbra's average media sentiment score of 1.16 beat Lantheus' score of 0.81 indicating that Penumbra is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ITGR or PEN?

Penumbra has lower revenue, but higher earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Integer $1.85B 2.31 $102.81M $3.66 34.44 Penumbra $1.40B 8.92 $177.69M $4.07 78.10

Is ITGR or PEN more profitable?

Penumbra has a net margin of 10.67% compared to Integer's net margin of 6.97%. Integer's return on equity of 12.79% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Integer 6.97% 12.79% 6.48% Penumbra 10.67% 10.50% 8.17%

Does the media prefer ITGR or PEN?

In the previous week, Integer had 1 more articles in the media than Penumbra. MarketBeat recorded 7 mentions for Integer and 6 mentions for Penumbra. Penumbra's average media sentiment score of 1.16 beat Integer's score of 0.20 indicating that Penumbra is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integer 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Penumbra 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IDXX or PEN?

In the previous week, IDEXX Laboratories had 12 more articles in the media than Penumbra. MarketBeat recorded 18 mentions for IDEXX Laboratories and 6 mentions for Penumbra. Penumbra's average media sentiment score of 1.16 beat IDEXX Laboratories' score of 1.13 indicating that Penumbra is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEXX Laboratories 13 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Penumbra 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, PEN or DXCM?

DexCom has higher revenue and earnings than Penumbra. DexCom is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Penumbra $1.40B 8.92 $177.69M $4.07 78.10 DexCom $4.97B 6.31 $836.30M $2.53 32.82

Is PEN or DXCM more profitable?

DexCom has a net margin of 20.12% compared to Penumbra's net margin of 10.67%. DexCom's return on equity of 35.94% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Penumbra 10.67% 10.50% 8.17% DexCom 20.12% 35.94% 14.75%

Does the media favor PEN or DXCM?

In the previous week, DexCom had 8 more articles in the media than Penumbra. MarketBeat recorded 14 mentions for DexCom and 6 mentions for Penumbra. Penumbra's average media sentiment score of 1.16 beat DexCom's score of 0.89 indicating that Penumbra is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 7 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, PEN or RMD?

ResMed has higher revenue and earnings than Penumbra. ResMed is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Penumbra $1.40B 8.92 $177.69M $4.07 78.10 ResMed $5.65B 5.57 $1.52B $10.43 20.93

Is PEN or RMD more profitable?

ResMed has a net margin of 26.94% compared to Penumbra's net margin of 10.67%. ResMed's return on equity of 25.58% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Penumbra 10.67% 10.50% 8.17% ResMed 26.94% 25.58% 18.89%

Does the media refer more to PEN or RMD?

In the previous week, ResMed had 8 more articles in the media than Penumbra. MarketBeat recorded 14 mentions for ResMed and 6 mentions for Penumbra. Penumbra's average media sentiment score of 1.16 beat ResMed's score of 1.11 indicating that Penumbra is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ResMed 12 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Penumbra (PEN) Competitors

$317.86 +0.08 (+0.03%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$317.73 -0.13 (-0.04%)

As of 09/11/2026 07:30 PM Eastern

Compare

PEN vs. LNTH, ITGR, IDXX, DXCM, and RMD

Should you buy Penumbra stock or one of its competitors? Penumbra's main competitors and comparable companies include Lantheus (LNTH), Integer (ITGR), IDEXX Laboratories (IDXX), DexCom (DXCM), and ResMed (RMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Penumbra compare to Lantheus?

Penumbra (NYSE:PEN) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Penumbra has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market.

In the previous week, Lantheus had 1 more articles in the media than Penumbra. MarketBeat recorded 7 mentions for Lantheus and 6 mentions for Penumbra. Penumbra's average media sentiment score of 1.16 beat Lantheus' score of 0.81 indicating that Penumbra is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a net margin of 17.69% compared to Penumbra's net margin of 10.67%. Lantheus' return on equity of 28.10% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	10.67%	10.50%	8.17%
Lantheus	17.69%	28.10%	14.35%

88.9% of Penumbra shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 2.9% of Penumbra shares are held by company insiders. Comparatively, 1.7% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Penumbra presently has a consensus price target of $367.07, indicating a potential upside of 15.48%. Lantheus has a consensus price target of $108.11, indicating a potential upside of 7.84%. Given Penumbra's higher probable upside, analysts clearly believe Penumbra is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

Lantheus has higher revenue and earnings than Penumbra. Lantheus is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	8.92	$177.69M	$4.07	78.10
Lantheus	$1.54B	4.24	$233.56M	$4.14	24.21

Summary

Lantheus beats Penumbra on 10 of the 16 factors compared between the two stocks.

How does Penumbra compare to Integer?

Integer (NYSE:ITGR) and Penumbra (NYSE:PEN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

Integer presently has a consensus price target of $109.86, indicating a potential downside of 12.86%. Penumbra has a consensus price target of $367.07, indicating a potential upside of 15.48%. Given Penumbra's stronger consensus rating and higher probable upside, analysts clearly believe Penumbra is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

Penumbra has lower revenue, but higher earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	2.31	$102.81M	$3.66	34.44
Penumbra	$1.40B	8.92	$177.69M	$4.07	78.10

In the previous week, Integer had 1 more articles in the media than Penumbra. MarketBeat recorded 7 mentions for Integer and 6 mentions for Penumbra. Penumbra's average media sentiment score of 1.16 beat Integer's score of 0.20 indicating that Penumbra is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integer	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Penumbra	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.3% of Integer shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 1.1% of Integer shares are owned by insiders. Comparatively, 2.9% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Penumbra has a net margin of 10.67% compared to Integer's net margin of 6.97%. Integer's return on equity of 12.79% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	6.97%	12.79%	6.48%
Penumbra	10.67%	10.50%	8.17%

Integer has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

Summary

Penumbra beats Integer on 12 of the 16 factors compared between the two stocks.

How does Penumbra compare to IDEXX Laboratories?

IDEXX Laboratories (NASDAQ:IDXX) and Penumbra (NYSE:PEN) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

IDEXX Laboratories has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market. Comparatively, Penumbra has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

87.8% of IDEXX Laboratories shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 0.8% of IDEXX Laboratories shares are owned by insiders. Comparatively, 2.9% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

IDEXX Laboratories has higher revenue and earnings than Penumbra. IDEXX Laboratories is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.55B	8.73	$1.06B	$14.22	35.49
Penumbra	$1.40B	8.92	$177.69M	$4.07	78.10

In the previous week, IDEXX Laboratories had 12 more articles in the media than Penumbra. MarketBeat recorded 18 mentions for IDEXX Laboratories and 6 mentions for Penumbra. Penumbra's average media sentiment score of 1.16 beat IDEXX Laboratories' score of 1.13 indicating that Penumbra is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEXX Laboratories	13 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEXX Laboratories currently has a consensus target price of $747.00, suggesting a potential upside of 48.01%. Penumbra has a consensus target price of $367.07, suggesting a potential upside of 15.48%. Given IDEXX Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe IDEXX Laboratories is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

IDEXX Laboratories has a net margin of 25.03% compared to Penumbra's net margin of 10.67%. IDEXX Laboratories' return on equity of 71.96% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	25.03%	71.96%	33.60%
Penumbra	10.67%	10.50%	8.17%

Summary

IDEXX Laboratories beats Penumbra on 11 of the 16 factors compared between the two stocks.

How does Penumbra compare to DexCom?

Penumbra (NYSE:PEN) and DexCom (NASDAQ:DXCM) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

DexCom has a net margin of 20.12% compared to Penumbra's net margin of 10.67%. DexCom's return on equity of 35.94% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	10.67%	10.50%	8.17%
DexCom	20.12%	35.94%	14.75%

Penumbra currently has a consensus price target of $367.07, suggesting a potential upside of 15.48%. DexCom has a consensus price target of $88.71, suggesting a potential upside of 6.84%. Given Penumbra's higher possible upside, equities analysts clearly believe Penumbra is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
DexCom	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.92

88.9% of Penumbra shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 2.9% of Penumbra shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Penumbra has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, DexCom has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market.

DexCom has higher revenue and earnings than Penumbra. DexCom is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	8.92	$177.69M	$4.07	78.10
DexCom	$4.97B	6.31	$836.30M	$2.53	32.82

In the previous week, DexCom had 8 more articles in the media than Penumbra. MarketBeat recorded 14 mentions for DexCom and 6 mentions for Penumbra. Penumbra's average media sentiment score of 1.16 beat DexCom's score of 0.89 indicating that Penumbra is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

DexCom beats Penumbra on 11 of the 17 factors compared between the two stocks.

How does Penumbra compare to ResMed?

Penumbra (NYSE:PEN) and ResMed (NYSE:RMD) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

ResMed has higher revenue and earnings than Penumbra. ResMed is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	8.92	$177.69M	$4.07	78.10
ResMed	$5.65B	5.57	$1.52B	$10.43	20.93

In the previous week, ResMed had 8 more articles in the media than Penumbra. MarketBeat recorded 14 mentions for ResMed and 6 mentions for Penumbra. Penumbra's average media sentiment score of 1.16 beat ResMed's score of 1.11 indicating that Penumbra is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ResMed	12 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.9% of Penumbra shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 2.9% of Penumbra shares are held by company insiders. Comparatively, 0.7% of ResMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Penumbra has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, ResMed has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

ResMed has a net margin of 26.94% compared to Penumbra's net margin of 10.67%. ResMed's return on equity of 25.58% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	10.67%	10.50%	8.17%
ResMed	26.94%	25.58%	18.89%

Penumbra presently has a consensus target price of $367.07, indicating a potential upside of 15.48%. ResMed has a consensus target price of $240.31, indicating a potential upside of 10.09%. Given Penumbra's higher probable upside, analysts clearly believe Penumbra is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
ResMed	0 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

ResMed beats Penumbra on 10 of the 16 factors compared between the two stocks.

Get Penumbra News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PEN vs. The Competition

Export

Metric	Penumbra	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$12.52B	$5.38B	$7.13B	$23.17B
Dividend Yield	N/A	1.79%	2.56%	3.56%
P/E Ratio	78.10	25.09	275.24	28.71
Price / Sales	8.92	82.90	656.02	94.44
Price / Cash	73.92	32.53	77.04	33.82
Price / Book	8.72	5.97	10.33	4.74
Net Income	$177.69M	$150.75M	$3.50B	$1.07B
7 Day Performance	-1.37%	-2.83%	-3.32%	-2.00%
1 Month Performance	-2.69%	-3.09%	-0.41%	-2.69%
1 Year Performance	16.20%	9.34%	19.21%	10.45%

Penumbra Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PEN Penumbra	3.5503 of 5 stars	$317.86 +0.0%	$367.07 +15.5%	+14.9%	$12.52B	$1.40B	78.10	4,700	Positive News
LNTH Lantheus	3.6328 of 5 stars	$100.97 flat	$108.11 +7.1%	+82.3%	$6.59B	$1.54B	24.39	1,193	News Coverage Positive News Analyst Downgrade
ITGR Integer	2.5072 of 5 stars	$126.40 -0.1%	$109.86 -13.1%	+21.1%	$4.30B	$1.85B	34.54	11,000	Insider Trade Options Volume
IDXX IDEXX Laboratories	4.1959 of 5 stars	$535.38 flat	$747.00 +39.5%	-21.8%	$42.18B	$4.30B	37.65	11,000	News Coverage Positive News Insider Trade
DXCM DexCom	3.4517 of 5 stars	$87.90 flat	$88.71 +0.9%	+9.3%	$33.17B	$4.66B	34.74	11,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PEN) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Penumbra (PEN) Competitors